In summary, ERICCIN is a single-centre, randomiseddouble-blinded placebo-controlled trial that will investigatewhether RIC can improve the rate of CIN followingiodinated contrast exposure occurring following coronaryangiographic procedures. It will follow patients for3 months and will determine biochemical outcome data aswell as collecting data related to cardiovascular and allcause mortality for the duration of follow-up. The findingswill have the potential to influence a change of clinicalpractice: RIC is a simple, non-invasive intervention that ischeap to deploy in an area where there are few, if any,effective alternatives